Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 3/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 3/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093964 | 0.83 | SCN1A (0.54) | KEAP1KMT2ASCN1ASCN5ASCN8A | |
| SCHEMBL6292016 | 0.78 | SLC40A1 (0.55) | SLC40A1GLO1CKS1BSKP2KEAP1 | |
| Formic Acid SCHEMBL19616986 | 0.77 | SCN1A (0.49) | KEAP1SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL22634311 | 0.75 | KMT2A (0.54) | SLC40A1KMT2AMAPTSCN1ASCN5A | |
| SCHEMBL30845613 | 0.75 | SCN1A (0.49) | SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL16720161 | 0.75 | SCN1A (0.48) | CA2SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL31017724 | 0.75 | SCN1A (0.44) | SCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL11704625 | 0.74 | SMN1; SMN2 (0.56) | KMT2AMAPTSCN1ASCN5ASCN8A | |
| SCHEMBL25382203 | 0.73 | SMN1; SMN2 (0.52) | SLC40A1GLO1CKS1BSKP2KEAP1 | |
| SCHEMBL31017719 | 0.73 | MAPT (0.46) | MAPTSCN1ASCN5ASCN8ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638898-B | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2024-04-09 | — | — | CN | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SLC40A1 3958/4885GLO1 2222/4885CKS1B 2074/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SLC40A1 3958/4885GLO1 2222/4885CKS1B 2074/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SLC40A1 3958/4885GLO1 2222/4885CKS1B 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.